Approval · Notice of Compliance 30232 · 2023
VYXEOS: Notice of Compliance 30232
Issued March 1, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 30232
- Date
- March 1, 2023
- Company
- Jazz Pharmaceuticals Ireland LimitedDublin, Dublin, Ireland
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| VYXEOS | Not yet assigned | — |
Medicinal ingredients
- CYTARABINE 100 MG per VIAL
- DAUNORUBICIN 44 MG per VIAL